Neurofit Corporate Research Institute Designated as Excellent Corporate Research Institute by Ministry of Science and ICT

[Asia Economy Reporter Park Hyungsoo] Neurophyt, a specialized AI solution company for brain diseases, announced on the 30th that its affiliated corporate research institute has been designated as an Excellent Corporate Research Center (ECRC) by the Ministry of Science and ICT.

The Excellent Corporate Research Center designation system, led by the Ministry of Science and ICT, evaluates the competitiveness and potential of technological innovation and supports corporate research centers with outstanding R&D capabilities. The evaluation targets small and medium-sized enterprises and mid-sized companies that have operated corporate research centers for more than three years in major industries such as science, technology, and services, and have excellent research and development capabilities, continuously creating value through technology commercialization or showing high potential.

Experts from various fields participated as evaluators and recognized Neurophyt's corporate affiliated research institute for its outstanding capabilities and technological innovation activities in all areas including financial soundness, technology development and commercialization status, certification and intellectual property rights, and R&D, leading to its selection as an Excellent Corporate Research Center.

Neurophyt is a company developing AI-based brain diagnosis, treatment, and prevention software. It has been recognized for its technological prowess in the field of dementia diagnosis brain imaging MRI analysis and attracted investment worth 10.6 billion KRW.

In September, Neurophyt developed the dementia diagnosis assistance solution ‘Neurophyt AQUA (NEUROPHET AQUA)’, which enables rapid judgment of brain atrophy that is difficult for radiologists to distinguish with the naked eye, and received approval from the Ministry of Food and Drug Safety. Based on this technology, it was also selected for the Dementia Overcoming Research and Development Project Group and the Pan-Governmental Full-Cycle Medical Device R&D Project.

Kim Donghyun, head of Neurophyt’s research institute, said, "Through the designation as an Excellent Corporate Research Center, Neurophyt’s technology and R&D capabilities have been externally recognized," adding, "We will strive to become a leading innovative company in the field of brain disease treatment and prevention and a frontrunner in overcoming dementia."

This content was produced with the assistance of AI translation services.